Expanded Access to ABT-414

Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis Clinical Trial

Official title:

Expanded Access to ABT-414

Clinical Trial Details — Status: No longer available

Administrative data

• NCT number: NCT03123952
• Other study ID #: C16-478
• Secondary ID: C19-919
• Status: No longer available

Study information

• Verified date: July 2019
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABT-414 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Recruitment information / eligibility

• Status: No longer available
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participant must have epidermal growth factor receptor (EGFR) amplification or EGFRvIII mutation.

• Health Care Provider (HCP) must have prior clinical trial experience with ABT-414.

• The participant must not be eligible for an ABT-414 clinical trial.

• Pediatric participants may be evaluated on a case by case basis.

Related Conditions & MeSH terms

• Glioblastoma
• Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis

Intervention

Drug:
• ABT-414
ABT-414 will be administered by intravenous infusion

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
AbbVie